FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901778890> ?p ?o ?g. }

• W2901778890 endingPage "94" @default.
• W2901778890 startingPage "1" @default.
• W2901778890 abstract "Background In septic shock, cardiovascular resuscitation using catecholamine vasopressors and inotropes is standard therapy, but catecholamines have important side effects. Levosimendan (Simdax ® ; Orion Pharma, Newbury, UK) is a calcium-sensitising drug with inotropic and other properties that may have a role in sepsis. Objectives To determine, in adult septic shock, whether or not levosimendan reduces the incidence and severity of acute organ dysfunction, the effect of levosimendan on individual organ function and the safety profile of levosimendan. Design Multicentre, randomised, double-blind, parallel-group, placebo-controlled study. Setting UK intensive care units. Participants Adult patients with sepsis and cardiovascular failure requiring vasopressors to maintain blood pressure despite adequate fluid resuscitation. Intervention Levosimendan, at a dosage of 0.05–0.2 µg/kg/minute, compared with placebo for 24 hours, in addition to standard care, within 24 hours of meeting inclusion criteria. Main outcome measure The primary outcome was mean Sequential Organ Failure Assessment (SOFA) score on the intensive care unit after randomisation to a maximum of 28 days. Secondary outcomes were time to extubation, survival up to 6 months and serious adverse events. Results In total, 2382 patients were screened at 34 centres, of whom 516 were randomised to treatment, 259 to levosimendan and 257 to placebo. Baseline characteristics were well balanced across treatment arms. There was no significant difference in mean ± standard deviation (SD) SOFA score between the levosimendan group (6.7, SD 4.0) and the placebo group (6.1, SD 3.9) [mean difference 0.61, 95% confidence interval (CI) –0.07 to 1.29]. The 28-day mortality rate was 34.5% and 30.9% in the levosimendan and placebo groups, respectively (absolute difference 3.6%, 95% CI –4.5% to 11.7%). Patients in the levosimendan group were less likely to be successfully extubated over 28 days than patients in the placebo group (hazard ratio 0.77, 95% CI 0.60 to 0.97). More patients in the levosimendan group had supraventricular tachyarrhythmias (3.1% vs. 0.4%; absolute difference 2.7%, 95% CI 0.1% to 5.3%), but there was no overall difference in serious adverse events. Conclusions In the population of septic shock patients randomised to treatment in this study, the addition of levosimendan to standard medical care did not reduce organ dysfunction or mortality. Levosimendan was associated with a reduced likelihood of successful extubation and an increased risk of supraventricular tachyarrhythmias. Limitations This was a trial of levosimendan added to standard care rather than a comparison against an alternative inotrope such as dobutamine. No echocardiographic analyses were performed to provide detailed information about changes in myocardial function; therefore, this trial cannot provide guidance as to which inotrope (if any) is best to use in the management of sepsis if a very low cardiac index is present. Future work Levosimendan could be compared against dobutamine and placebo in patients with a very low cardiac output in sepsis to test which, if any, inotrope should be used in this select group. Trial registration Current Controlled Trials ISRCTN12776039. Funding This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. Study drugs were provided by Orion Pharma and additional research funds were provided by Tenax Therapeutics. The study was supported by the NIHR Biomedical Research Centre based at Imperial College, London, and the UK Intensive Care Foundation." @default.
• W2901778890 created "2018-11-29" @default.
• W2901778890 creator A5009297057 @default.
• W2901778890 creator A5011508338 @default.
• W2901778890 creator A5039269680 @default.
• W2901778890 creator A5041103166 @default.
• W2901778890 creator A5043194384 @default.
• W2901778890 creator A5045480389 @default.
• W2901778890 creator A5050958004 @default.
• W2901778890 creator A5054928970 @default.
• W2901778890 creator A5056772974 @default.
• W2901778890 creator A5061349826 @default.
• W2901778890 creator A5084530096 @default.
• W2901778890 creator A5086478476 @default.
• W2901778890 creator A5089118073 @default.
• W2901778890 creator A5089192790 @default.
• W2901778890 creator A5089361577 @default.
• W2901778890 creator A5090829173 @default.
• W2901778890 date "2018-11-01" @default.
• W2901778890 modified "2023-10-10" @default.
• W2901778890 title "Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT" @default.
• W2901778890 cites W1538461375 @default.
• W2901778890 cites W1748374584 @default.
• W2901778890 cites W1898928487 @default.
• W2901778890 cites W1902219579 @default.
• W2901778890 cites W1965118241 @default.
• W2901778890 cites W1965141578 @default.
• W2901778890 cites W1966561241 @default.
• W2901778890 cites W1967300023 @default.
• W2901778890 cites W1974873560 @default.
• W2901778890 cites W1975641106 @default.
• W2901778890 cites W1976561120 @default.
• W2901778890 cites W1992536611 @default.
• W2901778890 cites W2000528305 @default.
• W2901778890 cites W2000610154 @default.
• W2901778890 cites W2002694672 @default.
• W2901778890 cites W2005717288 @default.
• W2901778890 cites W2012864937 @default.
• W2901778890 cites W2018135213 @default.
• W2901778890 cites W2018531332 @default.
• W2901778890 cites W2020514126 @default.
• W2901778890 cites W2021222913 @default.
• W2901778890 cites W2024647297 @default.
• W2901778890 cites W2025155187 @default.
• W2901778890 cites W2027340403 @default.
• W2901778890 cites W2029992744 @default.
• W2901778890 cites W2032520387 @default.
• W2901778890 cites W2032772673 @default.
• W2901778890 cites W2039204850 @default.
• W2901778890 cites W2039662339 @default.
• W2901778890 cites W2043513395 @default.
• W2901778890 cites W2045290851 @default.
• W2901778890 cites W2060423353 @default.
• W2901778890 cites W2064301134 @default.
• W2901778890 cites W2064927551 @default.
• W2901778890 cites W2070677107 @default.
• W2901778890 cites W2078213367 @default.
• W2901778890 cites W2080744981 @default.
• W2901778890 cites W2081875144 @default.
• W2901778890 cites W2082854356 @default.
• W2901778890 cites W2085571400 @default.
• W2901778890 cites W2088444622 @default.
• W2901778890 cites W2089801572 @default.
• W2901778890 cites W2098538911 @default.
• W2901778890 cites W2100292802 @default.
• W2901778890 cites W2100820242 @default.
• W2901778890 cites W2104672570 @default.
• W2901778890 cites W2104996682 @default.
• W2901778890 cites W2105575181 @default.
• W2901778890 cites W2108130826 @default.
• W2901778890 cites W2108153775 @default.
• W2901778890 cites W2130956043 @default.
• W2901778890 cites W2132135347 @default.
• W2901778890 cites W2142798193 @default.
• W2901778890 cites W2143034699 @default.
• W2901778890 cites W2148706741 @default.
• W2901778890 cites W2151820845 @default.
• W2901778890 cites W2151936503 @default.
• W2901778890 cites W2152787571 @default.
• W2901778890 cites W2153670019 @default.
• W2901778890 cites W2154390395 @default.
• W2901778890 cites W2158659030 @default.
• W2901778890 cites W2159933802 @default.
• W2901778890 cites W2164679816 @default.
• W2901778890 cites W2170344041 @default.
• W2901778890 cites W2328609062 @default.
• W2901778890 cites W2401664022 @default.
• W2901778890 cites W2436288320 @default.
• W2901778890 cites W2489536306 @default.
• W2901778890 cites W2515625652 @default.
• W2901778890 cites W2529283167 @default.
• W2901778890 cites W3023757607 @default.
• W2901778890 cites W4210712363 @default.
• W2901778890 cites W4235111205 @default.
• W2901778890 cites W4292528167 @default.
• W2901778890 doi "https://doi.org/10.3310/eme05060" @default.
• W2901778890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30431749" @default.
• W2901778890 hasPublicationYear "2018" @default.

• next